ABT
$116.05
Abbott Laboratories
($1.20)
(1.02%)
ABT
Earnings Whisper ®
$1.22
3rd Quarter September 2024
Consensus:  $1.20
Revenue:  $10.53 Bil
Wednesday
Oct 16
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ABT reports earnings?
Beat
Meet
Miss

Where is ABT's stock price going from here?
Up
Flat
Down
Stock chart of ABT
Analysts
Summary of analysts' recommendations for ABT
Score
Grade
Pivots
Resistance
$120.22
$119.29
$117.67

$116.74

Support
$115.12
$114.19
$112.57
Tweet
Growth
Description
Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.
Peers
Boston ScientificStrykerWatersBecton, Dickinson3MBaxter InternationalTeleflexResMedIntegra LifeSciences HoldingsMerit Medical Systems